Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05382637 · ClinicalTrials.gov registry record · Phase 2
Growth Hormone in a Patient With a Dominant-Negative GHR Mutation
A Phase 2 study of Growth Disorders, sponsored by Children's National Research Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT05382637 is a Phase 2 study of Growth Disorders that is active but no longer recruiting, run by Children's National Research Institute. The registered enrollment target is 1 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05382637, a Phase 2 study of Growth Disorders, is active but no longer recruiting, sponsored by Children's National Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective interventional study designed for a single patient with a dominant-negative mutation in the growth hormone receptor gene (GHR) which results in increased levels of growth hormone binding protein (GHBP). The patient will receive escalating doses of growth hormone titrated to achieve an insulin like growth factor-1 level above the mean and then growth response to therapy will be monitored.
Conditions Studied
Interventions
- DRUG Somatropin
Study Locations (1)
District of Columbia
- Children's National Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-08-26 |
| Est. Completion | 2028-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05382637
The ClinicalTrials.gov registry entry for NCT05382637 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's National Research Institute, which has 92 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Growth Disorders appearing as the primary indexed condition, and to 1 intervention - of which Somatropin is the first listed.
NCT05382637 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05382637 about?
NCT05382637 is a clinical study titled "Growth Hormone in a Patient With a Dominant-Negative GHR Mutation". This is a prospective interventional study designed for a single patient with a dominant-negative mutation in the growth hormone receptor gene (GHR) which results in increased levels of growth hormone binding protein (GHBP). The patient will receive escalating doses of growth hormone titrated to ach...
What is the current status of trial NCT05382637?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2022-08-26. Estimated completion is 2028-09-01.
What conditions does trial NCT05382637 study?
This clinical trial studies the following conditions: Growth Disorders.
What interventions are being tested in trial NCT05382637?
The interventions under investigation include: Somatropin (DRUG).
Who is sponsoring clinical trial NCT05382637?
This trial is sponsored by Children's National Research Institute, which has 92 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05382637 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Growth Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.